Search research articles
Contact Us
Filters
Showing results (131-140 of 147) with videos related to
Page
of 15
Sort By:
The Oncologist
|
October 15, 2015
A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study
Hye Sook Han, Ji Chan Park, Suk Young Park, et al.
Oncology Reports
|
May 9, 2015
Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidine-based chemotherapy
Ho-Young Yhim, Sang-Hee Cho, Sam Yong Kim, et al.
JCO Global Oncology
|
April 10, 2026
Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study
Bhumsuk Keam, Darren Wan-Teck Lim, Hsiang-Fong Kao, et al.
Cancer Science
|
July 30, 2021
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer
Satoru Iwasa, Kei Muro, Satoshi Morita, et al.
The Lancet. Oncology
|
October 16, 2012
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial
Yong Sang Hong, Young Suk Park, Ho Yeong Lim, et al.
Cancer Research and Treatment
|
December 11, 2025
Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup-Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOW
Keun-Wook Lee, Sang Cheul Oh, Jong Gwang Kim, et al.
Chinese Journal of Cancer
|
December 24, 2016
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
Masahito Kotaka, Ruihua Xu, Kei Muro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2023
Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial
Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, et al.
BMC Cancer
|
November 27, 2014
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
Seung Tae Kim, Yong Sang Hong, Ho Yeong Lim, et al.
The Korean Journal of Internal Medicine
|
November 28, 2017
The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study
Jae Ho Byun, Joong Bae Ahn, Sun Young Kim, et al.
Page
of 15
Search research articles
Search
Showing results (131-140 of 147) with videos related to
Sort By:
Page
of 15
The Oncologist
|
October 15, 2015
A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A Korean South West Oncology Group Study
Hye Sook Han, Ji Chan Park, Suk Young Park, et al.
Oncology Reports
|
May 9, 2015
Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidine-based chemotherapy
Ho-Young Yhim, Sang-Hee Cho, Sam Yong Kim, et al.
JCO Global Oncology
|
April 10, 2026
Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study
Bhumsuk Keam, Darren Wan-Teck Lim, Hsiang-Fong Kao, et al.
Cancer Science
|
July 30, 2021
Impact of UGT1A1 genotype on the efficacy and safety of irinotecan-based chemotherapy in metastatic colorectal cancer
Satoru Iwasa, Kei Muro, Satoshi Morita, et al.
The Lancet. Oncology
|
October 16, 2012
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial
Yong Sang Hong, Young Suk Park, Ho Yeong Lim, et al.
Cancer Research and Treatment
|
December 11, 2025
Zolbetuximab Plus Chemotherapy as First-Line Treatment in Patients with Claudin 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: Korean Population Subgroup-Combined Efficacy and Safety Analysis from SPOTLIGHT and GLOW
Keun-Wook Lee, Sang Cheul Oh, Jong Gwang Kim, et al.
Chinese Journal of Cancer
|
December 24, 2016
Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab
Masahito Kotaka, Ruihua Xu, Kei Muro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 12, 2023
Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial
Bhumsuk Keam, Min Hee Hong, Seong Hoon Shin, et al.
BMC Cancer
|
November 27, 2014
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
Seung Tae Kim, Yong Sang Hong, Ho Yeong Lim, et al.
The Korean Journal of Internal Medicine
|
November 28, 2017
The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study
Jae Ho Byun, Joong Bae Ahn, Sun Young Kim, et al.
Page
of 15